Webb23 feb. 2024 · Shantha Biotechnics’ successful development of recombinant products heralded the bio-pharma revolution in India which motivated many scientists and entrepreneurs to develop and produce life-saving drugs indigenously. Under his leadership, Shantha Biotechnics won several awards for the company’s contribution in the field of … Webb716 Likes, 7 Comments - Vindhya Vishaka (@vindhya_vishaka) on Instagram: "Happy To be a Part of Shantha Biotech's 25 years celebrations @RamojiFilmcity #AnchorVin..." Vindhya Vishaka on Instagram: "Happy To be a Part of Shantha Biotech's 25 years celebrations @RamojiFilmcity 😊💐 #AnchorVindhya #ShanthaFamily 😊"
Shantha Biotechnics Limited,Part of Sanofi Aventis Group
WebbShantha Biotech MD Dr KI Varaprasad Reddy Business R&D and manufacture of human therapeutics Start-up Year: 1993 Address:€ H.No.5-10-173, 3rd & 4th Floors, Vasantha … WebbPartha. Website. http://[email protected]. Industries. Biotechnology Research. Company size. 501-1,000 employees. Type. Public Company. birth chip and kipper
Dr. K I Varaprasad Reddy Shantha Biotech India
Shantha Biotechnics Limited is an Indian biotechnology company headquartered in Hyderabad, India. It is the first Indian company to develop, manufacture and market recombinant human healthcare products in India. The company is a wholly owned subsidiary of Sanofi group. Shantha Biotechnics caters to major international markets including Asia-Pacific, Africa, Commonwealth of Independent States, and Latin America in addition to international organisatio… WebbFor the scientific mind to soar limitless horizons, a conducive environment is a primary requisite. In recognizing this need, Shantha has designed and developed a truly world-class research facility equipped with the latest tools of research in modern biotechnology, providing the scientists with the necessary wherewithal to carry on their work Shantha is … Webb27 juli 2009 · The deal between Sanofi its French owners Meriuex Alliance values the unlisted Indian company at Rs 3,740 crore, or about eight times its projected sales of Rs 440 crore for this fiscal. A valuation of eight times the sales is unheard of. If other companies get such an attractive valuation, they may be tempted to sell, said HDFC … birth choice clinic